Articles tagged with Glioblastomas
Brain cancer cells use mitochondria from healthy astrocytes to boost energy production and amplify cancer stem cells, making glioblastoma more deadly and difficult to treat. Researchers discovered that acquiring mitochondria is a common process in glioblastoma, with implications for developing new treatments.
Glioblastoma steals cognitive faculties as it spreads, but its insidious ability to infiltrate neighboring networks may be its undoing. Researchers found neural activity can restructure connections in surrounding tissue, causing decline. The drug gabapentin blocks this growth-causing activity in mice with glioblastoma.
A multi-institutional phase 3 clinical trial found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with recurrent glioblastoma. ChemoID, a CLIA-accredited diagnostic test, was used to select chemotherapy treatments, resulting in significantly lower risk of death a...
Scientists successfully opened the blood-brain barrier using a novel ultrasound device, delivering chemotherapy to treat glioblastoma patients. The treatment increased drug concentrations by 4-6 times and was safe and well-tolerated.
Researchers identified three novel dual-purpose therapeutic targets using PandaOmics, which could treat both aging and glioblastoma multiforme. The target hypotheses include cyclic nucleotide gated channel subunit alpha 3 (CNGA3), glutamate dehydrogenase 1 (GLUD1) and sirtuin 1 (SIRT1).
Three high school students co-authored a paper using AI engine PandaOmics to discover new therapeutic targets for glioblastoma multiforme, a common and aggressive malignant brain tumor. The study identified three genes strongly correlated with both aging and glioblastoma as potential therapeutic targets.
A novel gel has cured 100% of mice with aggressive brain cancer, a breakthrough that could lead to new treatments for glioblastoma. The gel combines an anticancer drug and antibody to target tumor cells and stimulate the immune system.
A team of researchers has discovered that a naturally produced chemical in the body helps glioblastoma cells go unrecognized by the immune system. The findings could lead to the development of new and more effective treatments for this aggressive brain cancer.
Researchers develop mechanical nanosurgery to destroy tumour cells from within, reducing GBM tumour size universally, including in TMZ-resistant cases. The treatment uses magnetically controlled carbon nanotubes to provide mechanical stimulation, damaging cellular structures and causing tumour cell death.
Dominique Higgins and his team found that a specialized diet can induce ferroptosis, a type of cell death, in glioblastoma cells, making chemotherapy drugs more effective. This approach has shown promise in animal models and is being explored as a potential treatment for brain tumors.
Researchers discovered that tumors with specific genetic mutations may evade the immune system, and a new class of immunotherapies targets these cells. The study's findings suggest that genetic testing could identify patients more likely to benefit from these therapies.
Two compounds, A5 and C1, have shown promising results in inhibiting the growth of glioblastoma cells, a type of aggressive brain cancer. Further research is needed to confirm their effectiveness on normal nerve cells and to move towards clinical trials.
Researchers at Penn State College of Medicine identified a biomarker, IL13Rα2, in blood plasma to diagnose and track glioblastoma. Elevated levels of IL13Rα2 predicted longer overall survival, suggesting tissue healing.
Researchers identify the minimum contribution of TACC3 for FGFR3-TACC3 fusion protein activation, revealing a novel target for treating FGFR translocation-driven cancers. The study shows that clinically identified FGFR3-TACC3 fusion proteins differ in biological activity depending on specific breakpoints.
Glioblastoma patients have a median survival time of 15 months due to the rapid infiltration of brain tissue. Cellular senescence, previously thought to be only a marker of aging, is now linked to cancer progression, with senescent cells promoting tumor growth and immune evasion.
Researchers have developed a sophisticated AI algorithm, SPHINKS, that can refine omics datasets and pinpoint protein kinases responsible for tumor growth in glioblastoma. The algorithm has the potential to provide personalized treatments for patients with aggressive brain cancer.
Researchers at Massachusetts General Hospital found that losartan can reduce the expression of inflammatory enzymes responsible for immunotherapy-related edema. The study suggests that losartan may allow patients to continue receiving immune checkpoint inhibitors without developing adverse effects in the brain.
Researchers from UTSA and UT Health San Antonio are developing compounds that target the estrogen receptor-beta, which suppresses cancer growth. The goal is to identify a novel ER-beta agonist with potential as a therapeutic strategy for treating GBM in patients.
Researchers are launching a clinical trial testing azeliragon, a RAGE inhibitor, with chemoradiotherapy to re-sensitize brain tumours that resist radiotherapy. The trial aims to predict radioresistance in brain metastasis using liquid biopsy.
A team of researchers from Korea and USA identified the importance of lipid homeostasis in overcoming brain cancer radioresistance. They found that regulating diacylglycerol kinase B and diacylglycerol acyltransferase 1 could potentially sensitize brain cancer cells to radiotherapy, offering a new treatment strategy.
A new study led by Massachusetts General Hospital researchers reveals that an investigational drug called YTX-7739 can delay the growth of brain tumors and increase their sensitivity to conventional chemotherapy. The drug works by inhibiting de novo lipid synthesis, a process used by cancer cells for energy production.
A team of researchers from Cold Spring Harbor Laboratory has made a breakthrough in understanding the deadly brain cancer glioblastoma. By linking the BRD8 protein to another key protein, P53, they have identified a potential target for new treatments that could extend patient survival and improve outcomes.
UCSF researchers identified glioma's cellular source of recurrent disease, finding cells shift to mesenchymal, radiation-resistant phenotype in response to standard therapy. Paracrine signals from tumor microenvironment drive this transition through AP1 pathway, leading to therapy resistance and tumor recurrence.
Researchers have identified three new subtypes of glioblastoma, a type of brain cancer, based on the presence of specific non-cancer cells. These subtypes may help identify targeted therapies, such as immunotherapies, for improved patient outcomes.
Researchers at UCLA Health have made significant breakthroughs in understanding deadly brain cancer and the role of housing interventions. A study found a cancer vaccine to be highly effective in treating glioblastoma multiforme, a nearly lethal brain cancer. Additionally, a survey highlighted the need for increased diversity in gastro...
A study published in Trends in Cancer suggests that targeting vulnerabilities in glioblastoma cancer cells, which maintain resemblance to the cells of origin, may lead to effective therapies. The research aims to identify ways to block these identity shifts and develop personalized treatments.
Kevin McHugh, a Rice bioengineer, has received the Distinguished Scientist Award from The Sontag Foundation for his work on gene editing to defeat glioblastoma multiforme. His approach involves delivering gene therapy agents directly to tumor cells, aiming to improve survival and reduce side effects.
Researchers demonstrate a new way to deliver medication to malignant brain tumors in mice, using a modified peptide that can penetrate the blood-brain barrier. The study shows promising results, with a 50% increase in survival rate for treated mice, and offers hope for future treatment breakthroughs.
A new study successfully tested an implantable pump that delivers chemotherapy directly to the brain, bypassing the blood-brain barrier. The treatment effectively kills brain tumor cells and offers a safe way to treat patients with brain cancer.
Researchers found that reducing SAMHD1 levels made brain tumor cells sensitive to chemotherapy drugs and slowed cell growth. They also suspect that glioblastoma alters SAMHD1's function to aid its own survival and treatment resistance.
A critical new pathway to treating glioblastoma, a deadly brain tumor, may be found in the complex diversity of tumor tissue. CDI scientists identified lipids with potential therapeutic value, highlighting the importance of targeting signaling pathways in relation to cell function and resistance to therapy.
The study found that BRAF alterations, particularly Class I mutations like v600E, are associated with improved overall survival in adults with glioma. However, the effectiveness of targeted therapies depends on the specific type and combination of genetic alterations driving the cancer.
Researchers at UCLA Jonsson Comprehensive Cancer Center and Semel Institute identified the gene P300 as a potential therapeutic target for treatment-resistant brain cancer glioblastoma multiforme. By blocking P300, tumor cells can be prevented from recovering and growing under the hostile conditions created by radiation therapy.
WayPath Pharma has been awarded a $225,000 Phase I Small Business Technology Transfer (STTR) award to develop new metabolic drugs targeting tumor stem cells and crossing the blood-brain barrier. The funding aims to advance treatment options for glioblastoma, a highly aggressive brain cancer with limited treatment options.
A new study has uncovered a previously unknown genetic process that could inform the development of novel treatment options for glioblastoma (GBM), a virtually incurable brain tumor. The epidermal growth factor receptor (EGFR) signaling pathway and long non-coding RNA molecules, such as lncEPAT, play critical roles in GBM tumorigenesis.
Researchers have identified a small molecule drug, SHP656, that can target the circadian clock proteins responsible for glioblastoma's recurrence and spread. The drug has shown promise in reducing cancer stem cell growth without harming normal stem cells.
A potential new treatment for glioblastomas, a deadly form of brain tumor, is being researched using the medication letrozole. Studies have shown that letrozole can be effective in killing tumor cells and reaching target tissue safely.
Monon Bioventures has received a grant to develop a novel glioblastoma treatment using armed natural killer cells. The treatment, created by Purdue University researcher Sandro Matosevic, shows promise in preclinical proof of concept and aims to manufacture the therapeutic for clinical studies.
Researchers at Tel Aviv University develop a groundbreaking method to eradicate glioblastoma brain tumors by targeting astrocytes and starving them of energy. The study found that in the absence of these brain cells, tumor cells die and are eliminated, offering a promising basis for developing effective medications.
UT Southwestern researchers have identified a molecular pathway responsible for glioblastoma's spread and found an existing drug that curbs tumor growth in animal models. A clinical trial is underway testing the effectiveness of tofacitinib in treating glioblastoma.
Researchers have developed an immunity-boosting postoperative treatment that could prevent glioblastoma relapse by targeting cancer stem cells with nanoparticles. The injectable gel promotes the cancer-killing immune response and reduces toxic side effects.
Researchers at University of Bristol developed mathematical models to assess biomarkers for detecting glioblastomas, a type of brain cancer. The study found that lowering the current biomarker threshold could lead to earlier detection using blood tests.
A novel T cell bispecific antibody targeting EGFRvIII mutant glioblastoma has demonstrated potent anti-tumor activity in preclinical models. The therapy harnesses the power of the immune system to selectively target and destroy cancer cells, offering a safer treatment option for patients.
Virginia Tech scientists have developed a novel 3D tissue-engineered model of the glioblastoma tumor microenvironment to learn why tumors return and what treatments will be most effective. The model accounts for cell types, fluid flow, and other aspects of the actual tumor environment, allowing for easy testing of drug therapies.
Researchers discover gene AVIL responsible for deadly brain tumor also causes two forms of childhood cancer, rhabdomyosarcoma. Blocking AVIL activity prevents formation of the disease in lab samples and mouse models.
Researchers have developed a biomimetic formulation to treat glioblastoma by harnessing lactate metabolism. The formulation, called M@HLPC, uses nanoparticles to deliver a combination of drugs that inhibit cancer cell growth and kill glioma cells.
Biomarkers have been identified that could be targeted by novel drugs to treat glioblastoma brain tumors, which are highly lethal. The researchers found that temozolomide-resistant glioblastoma relies on a protein called CLK2, and that inhibiting its activity can cause widespread cancer cell death.
Researchers have developed a molecule that uses nanotechnology, chemotherapy and a monoclonal antibody to target glioblastoma multiforme, the most aggressive type of brain cancer. The treatment showed promise in isolated cells and animal models, with significant reductions in tumor volume and no increased toxicity.
Researchers have reported encouraging early-stage data for the Phase 1 clinical trial of INB-200, a gamma-delta T cell-based immunotherapy. All patients enrolled in the trial have exceeded their expected progression-free survival, with two patients exceeding overall survival as well. The treatment shows promising activity against gliob...
Gliomas, a common brain and spinal cord tumor, undergo genetic evolution that alters their behavior at recurrence, leading to increased invasiveness and poorer prognosis. The study identified distinct phenotypes and cellular features associated with treatment resistance.
Researchers at MD Anderson Cancer Center found distinct gut microbiome signatures associated with immunotherapy response in patients with newly diagnosed glioblastoma. The study identified a link between gut microbiome signatures and immune checkpoint blockade response in melanoma, NSCLC, and sarcoma.
A team of MIT researchers has developed drug-carrying nanoparticles that can efficiently penetrate the brain and kill glioblastoma cells. Using a human tissue model, they showed that the particles could get into tumors and deliver chemotherapy drugs, including cisplatin, which effectively killed tumor cells.
Researchers have developed a novel therapeutic strategy for treating glioblastoma using allogenic stem cells that can target and kill tumor cells. The therapy demonstrated profound efficacy in preclinical models, with 100% of mice living over 90 days after treatment.
A receptor protein called insulin receptor is pivotal for brain stem cell longevity, according to a Rutgers study. The researchers also found that the same protein plays a crucial role in sustaining brain cancer cells.
A seven-year research project suggests that a short chain of amino acids, the HTL-001 peptide, is effective at targeting and inhibiting Hox genes responsible for GBM growth. The study offers hope for finding a solution to this devastating form of brain cancer.
Researchers have discovered a potential new treatment for glioblastoma, which targets 'kinase' proteins to limit tumour growth and improve existing chemotherapeutic drugs. This breakthrough therapy may provide hope for patients with aggressive brain tumours, offering a more effective and sustainable approach to treatment.
Researchers discovered a novel mechanism for miR-10b activation in high-grade gliomas, implicating topologic reorganization of chromatin and long-non-coding RNAs. This finding suggests new RNA-targeted strategies for glioma therapy and points to the vulnerability of tumor-initiating cells.
Glioblastomas, the deadliest brain cancer, have evaded immune cells by promoting immunosuppressive myeloid cells. Researchers identified S100A4 as a key molecule that can selectively target these immune suppressive cells. This discovery paves the way for new therapeutic strategies to restore antitumor action in glioblastoma patients.
Researchers at Okayama University have created a new method to kill cancer cells using light-activated protein AR3, reducing the risk of adverse reactions. The approach uses green light to trigger apoptosis in targeted cells, offering a promising alternative to conventional treatments.
Scientists have discovered anticancer substances in kudzu roots and soy molasses that can fight cancer, especially when chemotherapy or surgery are dangerous. The isoflavonoids in these plant extracts mimic human estrogen and bind to free radicals, leading to various diseases including cancer formation.